Hydroxyzine

CHEMBL896 Phase 4 Approved Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

374.9 g/mol

LogP

3.7

Phase

4

This first-generation antihistamine has anxiolytic, antipruritic, and sedative properties and is used to treat anxiety, itching from allergic conditions, and nausea. It works by blocking histamine H1 receptors and also affects other neurotransmitter systems in the brain. It does not carry the risk of dependence seen with benzodiazepines.

Molecular Weight

374.9000 g/mol

LogP

3.70

TPSA

35.90 Å²

Lipinski RO5

Pass

Therapeutic Areas

Asthma Atopic Dermatitis Breast Cancer Chronic Pain Colorectal Cancer Generalized Anxiety Disorder Major Depressive Disorder Migraine Multiple Sclerosis Non-Small Cell Lung Cancer Oncology Ovarian Cancer Pain Management Schizophrenia Type 2 Diabetes

Mechanism of Action

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanism

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, …

2D Structure

SVG PNG

Cite this structure

Embed this structure

SMILES

OCCOCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1

InChI

InChI=1S/C21H27ClN2O2/c22-20-8-6-19(7-9-20)21(18-4-2-1-3-5-18)24-12-10-23(11-13-24)14-16-26-17-15-25/h1-9,21,25H,10-17H2

Molecular Formula

C21H27ClN2O2

HBD / HBA

1 / 4

Rotatable Bonds

8

Heavy Atoms

26

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

This first-generation antihistamine has anxiolytic, antipruritic, and sedative properties and is used to treat anxiety, itching from allergic conditions, and nausea. It works by blocking histamine H1 receptors and also affects other neurotransmitter systems in the brain. It does not carry the risk of dependence seen with benzodiazepines.

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.

Yes, Hydroxyzine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL896. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 3658. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Looking for patient-friendly information?

Hydroxyzine on PillFYI

Structure

Quick Data

Formula: C21H27ClN2O2
Synonyms: 4

External Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.